New Tezepelumab Data Continue to Strengthen Profile for a Broad Population of Severe Asthma Patients

WILMINGTON, Del.--(BUSINESS WIRE)--Detailed results from the pivotal NAVIGATOR Phase III trial showed AstraZeneca and Amgen’s tezepelumab, a potential first-in-class treatment, demonstrated superiority across every primary and key secondary endpoint in a broad population of severe asthma patients, compared to placebo when added to standard of care (SoC). In one of...

Click to view original post